Shares of Zymeworks Inc. (NYSE:ZYME) have earned a consensus rating of “Hold” from the seven analysts that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $14.35.

ZYME has been the subject of several research reports. Zacks Investment Research raised Zymeworks from a “hold” rating to a “buy” rating and set a $7.75 target price for the company in a research report on Tuesday, November 14th. Cormark reissued a “buy” rating on shares of Zymeworks in a research report on Saturday, September 30th. Scotiabank lowered Zymeworks from an “overweight” rating to an “underweight” rating in a research report on Thursday, September 7th. Finally, Barclays PLC reaffirmed an “underweight” rating and set a $8.00 price objective on shares of Zymeworks in a research report on Thursday, September 7th.

A number of hedge funds have recently bought and sold shares of the stock. Franklin Resources Inc. bought a new position in Zymeworks during the 2nd quarter valued at approximately $6,878,000. Barometer Capital Management Inc. purchased a new stake in Zymeworks during the 2nd quarter valued at $484,000. Sentry Investments Corp. purchased a new stake in Zymeworks during the 2nd quarter valued at $206,000. Finally, OxFORD Asset Management LLP purchased a new stake in Zymeworks during the 2nd quarter valued at $154,000. 8.10% of the stock is owned by institutional investors.

Shares of Zymeworks (ZYME) traded up $0.11 during trading hours on Tuesday, hitting $8.27. The stock had a trading volume of 11,200 shares, compared to its average volume of 23,387. Zymeworks has a 12-month low of $6.25 and a 12-month high of $14.25.

TRADEMARK VIOLATION WARNING: This story was reported by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.watchlistnews.com/analysts-set-zymeworks-inc-zyme-pt-at-14-35/1724416.html.

Zymeworks Company Profile

Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company’s ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company’s platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins.

Analyst Recommendations for Zymeworks (NYSE:ZYME)

Receive News & Ratings for Zymeworks Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.